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Abstract
Background: Platinum-based systemic chemotherapy is considered the backbone for management of advanced
urothelial carcinomas. However there is a lack of real world data on the use of such chemotherapy regimens, on
patient profiles and on management after treatment failure.
Methods: Fifty-one randomly selected physicians from 4 European countries registered 218 consecutive patients in
progression or relapse following a first platinum-based chemotherapy. Patient characteristics, tumor history and
treatment regimens, as well as the considerations of physicians on the management of urothelial carcinoma were
recorded.
Results: A systemic platinum-based regimen had been administered as the initial chemotherapy in 216 patients: 15 in
the neoadjuvant setting, 61 in adjuvant therapy conditions, 137 in first-line advanced setting and 3 in other conditions.
Of these patients, 76 (35 %) were initially considered as cisplatin-unfit, mainly because of renal impairment (52 patients).
After platinum failure, renal impairment was observed in 44 % of patients, ECOG Performance Status≥ 2 in 17 %,
hemoglobinemia < 10 g/dL in 16 %, hepatic metastases in 13 %. 80 % of these patients received further anticancer
therapy. Immediately after failure of adjuvant/neoadjuvant chemotherapy, most subsequent anticancer treatments
were chemotherapy doublets (35/58), whereas after therapy failure in the advanced setting most patients receiving
further anticancer drugs were treated with a single agent (80/114). After first progression to chemotherapy, treatment
decisions were mainly driven by Performance Status and prior response to chemotherapy (>30 % patients). The most
frequent all-settings second anticancer therapy regimen was vinflunine (70 % of single-agent and 42 % of all subsequent
treatments), the main reasons evoked by physicians (>1 out of 4) being survival benefit, safety and phase III evidence.
Conclusion: In this daily practice experience, a majority of patients with urothelial carcinoma previously treated with a
platinum-based therapy received a second chemotherapy regimen, most often a single agent after an initial
chemotherapy in the advanced setting and preferably a cytotoxic combination after a neoadjuvant or adjuvant
chemotherapy. Performance Status and prior response to chemotherapy were the main drivers of further treatment
decisions.
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Background
More than 90 % of all cancers of the urinary tract are tran-
sitional cell carcinomas of the urothelium (urothelial car-
cinoma UC), 90 % being localized in the bladder [1, 2].
UC is a major health problem. In the European Union,
bladder cancer is the fifth most frequently diagnosed ma-
lignant tumor with more than 124,000 new cases in 2012
corresponding to 4.7 % of all human neoplasms. It ac-
counts for about 41,000 deaths in Europe [3].
Those patients with muscle-invasive UC are at high
risk of recurrence or progression, and half of them re-
lapse after radical surgery. The majority of relapses are
distant metastases and 10–15 % of patients are already
metastatic at diagnosis [4]. Metastatic UC is an aggres-
sive disease with a median survival not exceeding
6 months if untreated [5]. Chemotherapy plays an im-
portant role in the treatment of advanced stages of the
disease. For first-line treatment of advanced or meta-
static UC, a cisplatin-containing combination chemo-
therapy is considered the standard, either the classical
MVAC (methotrexate, vinblastine, adriamycin, cisplatin)
regimen or dose-dense MVAC and gemcitabine-cisplatin
regimens which are better tolerated [6, 7]. The median
survival is 13–15 months with these regimens in the
cisplatin-eligible patients [2, 6, 8]. However, up to 50 %
of patients are not eligible for a first-line cisplatin-
containing chemotherapy because of their poor perform-
ance status (PS) and/or comorbidities. For these pa-
tients, there is no clear standard treatment but a
carboplatin-based regimen or a single agent therapy are
considered acceptable alternatives, according to Euro-
pean guidelines [2, 8, 9].
A cisplatin-based neoadjuvant treatment is also rec-
ommended by clinical guidelines [2, 8, 10] for some
high-risk patients, before radical cystectomy. The role of
adjuvant chemotherapy is more controversial but a
meta-analysis of nine randomized trials and a large ob-
servational study suggested Disease-Free Survival and
Overall Survival (OS) benefits for the patients who re-
ceived cisplatin-based adjuvant chemotherapy [11, 12].
Second-line phase II data are highly variable with re-
sults depending on patient selection. Response rates for
treatment of relapse with mono-chemotherapy are lower
than those with combinations, but Progression-Free Sur-
vival and OS remain short with both options. In
addition, prognostic factors in second-line were only re-
cently established [13], making difficult the interpret-
ation of oldest study results.
After platinum-based chemotherapy failure, the only
chemotherapeutic agent approved in Europe is vinflu-
nine. Some physicians also consider of re-challenging
cisplatin-sensitive patients if progression occurs at least
6–12 months after first-line cisplatin-based combination.
Both treatment modalities are endorsed by clinical
guidelines (EAU, ESMO, ASCO) together with inclusion
in clinical trials [2, 8, 10].
Nevertheless, not all patients can benefit from second-
line therapy after they have progressed to a first
platinum-based chemotherapy. Probable reasons are the
drug prescription limitations, impaired general health
status that allows only best supportive care because of
potential adverse effects. In some cases, non-approved
drugs are used, based on physicians’ experience.
Most UCs are diagnosed at the superficial stage and it is
more complex to collect information on patients diagnosed
with an advanced or metastatic stage, which explains why
information on patient profiles and disease management is
very limited at time of second systemic treatment.
After decades of unmet medical need with no strong
evidence-based results and no specifically approved
drug, physicians treatment decision may vary a lot. In
addition there is no precise guidance according to the
patient profile and prognostic factors.
Thus, there is a need to better characterize these pa-
tients and clarify physicians’ practices. This could lead to
optimizing the use of available treatments.
The objective of this non-interventional study is to de-
fine the characteristics of patients when progression (re-
sistance or relapse) is demonstrated after a first systemic
platinum-based treatment and to report the physician’s
therapeutic attitudes both in theory from physician’s per-
spective and in daily practice according to the actual
characteristics of patients attending a consultation dur-
ing the survey period.
Methods
Study design
The study was a European ambispective survey reporting
epidemiology and practices in the management of
urothelial carcinoma (UC), following progression to a
platinum-based chemotherapy given in adjuvant, neoad-
juvant or metastatic settings.
The study aimed to draw an accurate picture of the
current practices. So it was formally requested that usual
medical practices should not be impacted by the study
process.
A total sample of 280 patients was planned from ap-
proximately 70 centers selected at random and located in
the participating countries: Austria, France, Italy and Spain.
The lists of centers in each country were established
on the basis the centers had physicians experienced in
the management of advanced or metastatic UC (≥6 pa-
tients/year).
The random lists of centers took into account the pri-
vate and public status of the institutions in accordance
with each country mode of management for the disease at
this stage. This led to a list of 171 physicians within the
four participating countries. Sixty-one out of 70 planned
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centers finally participated due to 9 late cancellations, and
51 centers actively recruited patients (Fig. 1).
All patients signed a specific informed consent if re-
quested or at least received detailed written information.
In compliance with the regulations of each participating
country, the study was approved by national authorities
as a non-interventional study and assessed by ethics re-
view boards of each participating institution, wherever
applicable.
Two types of information were collected:
Firstly, real-life patient data from case report forms.
Data were collected on the first series of consecutive
patients seen on a visit, with an expected number of 4
to 8 patients per center, up to a maximum of 10
patients in a given center during the study period.
Registered patients had to fit the inclusion criteria: age
over 18 years, locally advanced or metastatic UC,
pre-treatment with a platinum-based chemotherapy
(regardless of its setting: neoadjuvant chemotherapy,
adjuvant chemotherapy or palliative first-line in
advanced/metastatic disease), having shown progression
to the platinum-based treatment. Patients having
received prior platinum-free systemic chemotherapy
only were excluded.
Information collected included: initial patient
characteristics and prior treatments, patient
characteristics and comorbidities at the time of
progression, disease management in the post-platinum
setting.
Secondly, a questionnaire was filled by all participating
physicians regarding their practices, at the time of
patient inclusion. Physicians were asked how in theory
he/she should manage the patient (anticancer treatment
or alternatives) according to the patient characteristics
after one systemic platinum-based chemotherapy
regimen.
Statistics were mainly descriptive. Continuous data
were summarized using the following items: frequency,
median, range, mean, standard deviation and standard
error if relevant. Categorical data were presented in con-
tingency tables with frequencies and percentages of each
modality (including missing data modality). 95 % confi-
dence intervals were calculated following the exact
method. Furthermore, the relationship between the type
of therapy (monochemotherapy or combination) re-
ceived after progression and patient profiles after failure
of first platinum treatment, was assessed by both univar-
iate and multivariate analyses. In these exploratory ana-
lyses, a threshold of p < 0.05 was considered for
indicating a significant impact of patient characteristics.
Results
Two hundred and eighteen patients were included in the
study by 51 active centers between April 2013 and April
2014. The recruited patients were 104 in Italy, 54 in
Spain, 35 in France and 25 in Austria.
Centers and patients characteristics
The 51 active centers were located in Austria (n = 7),
France (n = 7), Italy (n = 21) and Spain (n = 16). The split
between public and private practice was 7/0 in Austria,
6/1 in France, 16/5 in Italy and 15/1 in Spain. Among
the 218 patients under study, 51 were followed in private
centers, and 167 in public centers.
The mean number of patients recruited per center was
4.3 (between 1 and 10). Thirty-four centers recruited up
to 4 patients, 11 centers between 5 and 9 patients, and 6
centers recruited 10 patients.
Of the 218 patients, 5 were excluded from the analysis
because 2 did not received any platinum-based chemo-
therapy and 3 had multiple different consecutive chemo-
therapy regimens. However, these patients were included
in the patient characteristics analysis.
Fig. 1 Flowchart of Center Selection and Patient Recruitment
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Males represented 84 % of the patients and median
age was 68. Thirty-three patients (15.1 %) were ≥ 75 years
old. Regarding the number of systemic chemotherapy
treatments at study entry, 45 patients (21 %) had re-
ceived just one previous chemotherapy regimen; 136
(62 %) had received 2 regimens, and 37 (17 %) had re-
ceived 3 or more regimens.
At registration, the treatment status of the patients
was: ongoing chemotherapy n = 140 (64 %), best sup-
portive care n = 42 (19 %), pending decision n = 28
(13 %) and other situations (i.e. remission period, pallia-
tive surgery) n = 8 (4 %).
Disease location at diagnosis was the bladder for 166
patients (76 %), upper urinary tract for 40 patients
(18 %), and urethra or other/multiple locations for 12
patients (6 %). The stages at diagnosis comprised non
muscle-invasive tumors for 24 patients (11 %), muscle-
invasive for 62 patients (28 %) and locally advanced or
metastatic disease for 132 patients (61 %). In this latter
group, 49 patients (22 %) had distant metastases at
diagnosis.
Most patients (n = 171 – 78 %) were initially treated
with surgery including radical cystectomy, partial cystec-
tomy or nephro-ureterectomy. Only 8 patients (4 %)
were treated by radiotherapy.
At the time of first platinum chemotherapy, 76 pa-
tients (35 %) were considered unfit for cisplatin, whereas
142 patients (65 %) were fit enough to receive a
cisplatin-based chemotherapy. Table 1 displays the rea-
sons for considering patients as unfit for cisplatin (some
patients may have had several reasons).
As first systemic chemotherapy, 123 (56 %) patients
received a cisplatin-based regimen and 93 (43 %) pa-
tients a carboplatin-based regimen. Two patients were
treated with a platinum-free regimen. Of the 213
patients who could be analyzed according to the setting
of their first systemic chemotherapy regimen, 76 patients
received their platinum therapy for neoadjuvant (15 pa-
tients) or adjuvant (61 patients) therapy objectives.
Among them, approximately one third (26 patients) was
treated with carboplatin and 50 patients with cisplatin.
Regarding the remaining 137 patients who received first-
line treatment for advanced disease, 66 were adminis-
tered carboplatin and 71 cisplatin-based regimen. 45 %
of patients (n = 61) displayed objective response, of
whom one third (n = 20) had complete response. 27 %
(n = 37) had disease stabilization and 26 % (n = 36) had
progressive disease. At the time of subsequent post-
platinum treatment decision, following treatment failure,
many patients had poor general conditions (Table 2).
Renal impairment was observed in 44 % of patients,
ECOG PS ≥ 2 in 17 %, hemoglobinemia <10 g/dl in
16 %, hepatic metastases in 13 %.
Only 63 (29 %) patients were considered as not having
any major constraint or co-morbid condition at the time
of subsequent treatment decision.
Despite their condition, most of the patients (n = 175
– 80 %) received further chemotherapy, 71 receiving
combination therapy and 104 monotherapy. Only 18 pa-
tients (8 %) were managed by best supportive care. The
remaining patients were waiting for treatment decisions
or managed by other options. The chemotherapy regi-
mens used after neoadjuvant/adjuvant platinum treat-
ments were most often (60 %) a combination therapy,
preferentially including a platinum agent. The main drug
combined with platinum was gemcitabine. On the other
hand, after platinum therapy given in the advanced set-
ting, the majority of patients (70 %) were treated with
Table 1 Conditions contributing to cisplatin ineligibility
Reason(s) for cisplatin-ineligibility n = 76
Single reason 66 (87 %)
Renal impairment only 44 (58 %)
PS≥ 2 only 9 (12 %)
Single reason not specified 7 (9 %)
Heart failure only 5 (7 %)
Hearing impairment only 1 (1 %)
Multiple reasons 10 (13 %)
PS≥ 2 + renal impairment 5 (7 %)
PS≥ 2 + heart failure 1 (1 %)
PS≥ 2 + other 1 (1 %)
Renal impairment + Hearing impairment 1 (4 %)
Renal impairment + other 1 (1 %)
Renal impairment + Hearing impairment + other 1 (1 %)
Other reasons included age or comorbidities
Table 2 Patient profile at time of post-platinum treatment
decision
Patient profile at time of post-platinum treatment
decision (number of available patients)
N %
Age (n = 218)
≥ 75 years 33 15
ECOG PS (n = 213)
PS 0/1 76/101 36/47
PS≥ 2 36 17
Renal impairment (n = 217)
Creatinine clearance < 60 mL/min 95 44
Creatinine clearance < 40 mL/min 25 12
Low hemoglobin value (n = 217)
< 10 g/dL 35 16
Neutropenia (or leucopenia) (n = 217) 6 3
Hepatic metastases (n = 216) 28 13
Hepatic impairment (n = 217) 6 3
Clinically relevant cardiac toxicity (n = 217) 13 6
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single-agent chemotherapy. Vinflunine represented 42 %
of all subsequent chemotherapy regimens and 70 % of
single agent therapy. Taxanes were the second type of
chemotherapy used, representing 22 % of single agent
therapy with paclitaxel being used 3.6 times more often
than docetaxel.
The different therapeutic options chosen are summa-
rized in Table 3.
In the descriptive analysis, the main patient character-
istics impacting the choice of any possible second-line
treatment were performance status (50 %), response to
previous chemotherapy (poor response: 33 %; good re-
sponse: 22 %), age (23 %), renal impairment (23 %), mul-
tiple comorbidities (7 %) and visceral metastases (7 %).
Additional univariate and multivariate analyses looked
into the association between patient characteristics at
the time of progression to the first systemic chemother-
apy and the subsequent treatment (single agent therapy
or polychemotherapy regimen). The explored patient pa-
rameters were the established prognostic factors in sec-
ond line (hemoglobinemia < 10 g/dL; ECOG PS; liver
metastases) and other characteristics considered to po-
tentially impact on treatment decision (age <75 or ≥ 75;
renal function – creatinine clearance below or over
60 mL/min; presence or not of cardiac toxicities; re-
sponse to prior systemic chemotherapy; regimen of ini-
tial chemotherapy (cisplatin-based or not); number of
cycles; reason of discontinuation of initial chemotherapy;
time to progression after initial systemic chemotherapy
and major toxicities during the course of prior cytotoxic
regimen). In univariate analysis, 4 factors were signifi-
cantly associated with either single agent or combination
therapy: hemoglobin level (p = 0.0034), response to ini-
tial chemotherapy (p < 0.0001), reason for discontinu-
ation (p = 0.002) and time to progression (p < 0.0001).
The multivariate analysis confirmed the association with
response to previous chemotherapy (p = 0.0356) and
time to progression (p = 0.0063), clearly impacting the
choice of subsequent treatment; hemoglobin level was at
the limit of significance (p = 0.0553).
Usual practices for first systemic chemotherapy
(according to physician’s questionnaire)
For the participating physicians (n = 51), the most com-
monly firstly used chemotherapy regimen is a doublet of
platinum plus gemcitabine, whether patients are fit or
not to receive cisplatin.
Tables 4 and 5 depict the preferred choices of physicians
for first systemic chemotherapy, in patients fit and unfit
for cisplatin, according to the setting (neoadjuvant-adju-
vant or palliative for advanced or metastatic disease).
Factors impacting treatment decisions following
progression or relapse to a first platinum-based therapy
(according to physician’s questionnaire)
Most physicians (42 out of 51, 82 %) declared that the
way they would theoretically manage the disease after a
progression or relapse does not really differ whether the
first systemic chemotherapy was administered in the
perioperative setting or as palliative first-line treatment.
The factors most impacting treatment decisions fol-
lowing progression or relapse to a first platinum-based
therapy are performance status (for 90 %), comorbidities
Table 3 Disease management immediately following failure of







Cisplatin-based 50 (66 %) 71 (52 %)
Carboplatin-based 26 (34 %) 66 (48 %)
Subsequent chemotherapy
n, (%)
58 (76 %) 114 (83 %)
Single agent 23 80
Vinflunine/Taxanes 15/5 57/18
Gemcitabine/Other agent 2/1 2/3






7 (9 %) 11 (8 %)
Pending decision or othera
n, (%)
11 (14 %) 12 (9 %)
aOther situations: scheduled surgery, radiotherapy or chemotherapy
Table 4 Preferred choices of physicians for first systemic
chemotherapy, in patients eligible for cisplatin
Usual physician chemotherapy regimen for 1st




As neoadjuvant or adjuvant chemotherapya
Missing -
MVAC 3 (5.9 %)
HD-MVAC 1 (2.0 %)
GEM-cisplatin 42 (82.4 %)
GEM-cisplatin or (HD)-MVAC 3 (5.9 %)
Other 3 (5.9 %)
As palliative first-line chemotherapy
Missing -
MVAC 2 (3.9 %)
HD-MVAC -
GEM-cisplatin 46 (90.2 %)
GEM-cisplatin or (HD)-MVAC 2 (3.9 %)
Other 1 (2.0 %)
a One physician ticked two answers
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(for 55 %), response to prior chemotherapy (for 43 %),
renal impairment (for 35 %) and progression-free inter-
val after prior chemotherapy (for 31 %). European guide-
lines, patients/families requests and drug access also
impact choices but for only 14, 10 and 8 % of the clini-
cians, respectively.
Best supportive care is not considered in patients with
PS 0–1 but only as possible option by 26 % of physicians
in case of PS ≥ 2 without associated renal impairment
and by 45 % in case of combined adverse conditions. A
vast majority of physicians consider in theory a single-
agent therapy in post-platinum setting whatever the PS
is (72–82 % of cases, except for patients having com-
bined PS ≥ 2 and impaired renal function for whom phy-
sicians balance treatment decision with best supportive
care −51–45 %). Only in patients with PS 0 and normal
renal function, a doublet is considered by 31 % of physi-
cians, with no standard regimen but gemcitabine-
cisplatin in more than a half of them.
Vinflunine is the most frequent treatment option in
patients with PS 0 or 1 independently of renal function
(34–38 physicians out of the set of 51: 67–75 %), but is
rarely perceived as a possible treatment in case of PS 2
(<8 %). The main reasons claimed by physicians for
using vinflunine (Table 6) are phase 3 study evidence
(67 %), safety profile (41 %), survival benefit (29 %) and
vinflunine European approval (26 %).
The second most frequent option is paclitaxel single
agent: 22–31 % of physicians, regardless of PS. Gemcita-
bine single agent is considered mainly in patients with
PS ≥ 2 but only by 4–12 % of physicians in patients with
PS 0–1.
Discussion
This observational study analyzes the clinical practice in
four European countries, reporting disease management
of advanced UC. It describes the proportion and main
characteristics of patients receiving a second systemic
anticancer treatment without the patient selection biases
related to drug clinical trials where patients are usually
included with good PS and few comorbidities. It is the
first survey assessing European routine medical practices
in advanced stages of UC previously treated with a
platinum-based chemotherapy. Two retrospective epi-
demiological studies were previously communicated as
abstracts. One assessed the type of platinum treatment
given in 298 patients with stage IV disease [14]. The sec-
ond retrospective data collection was conducted in se-
lected centers with the aim of assessing prognostic
factors of OS [15]. None provided such detailed infor-
mation on both first-line, subsequent treatments and pa-
tients characteristics in daily practice. This is of interest
considering the current gaps in clinical guidelines, in
particular for the management of patients with ECOG
Table 5 Preferred choices of physicians for first systemic
chemotherapy, in patients not eligible for cisplatin
Usual physician chemotherapy regimen for 1st line




As neoadjuvant or adjuvant chemotherapy
Missing -
Single agent -
Chemotherapy doublet 43 (84.3 %)
Gemcitabine-carboplatin 40 (78.4 %)
Paclitaxel-carboplatin 1 (2.0 %)
Docetaxel-carboplatin 1 (2.0 %)
Gemcitabine-Paclitaxel 1 (2.0 %)
Other 1 (2.0 %)
None 7 (13.7 %)
As palliative first-line chemotherapy
Missing -
Single agent 2 (3.9 %)
Gemcitabine 2 (3.9 %)
Carboplatin (carboplatin) -
Chemotherapy doublet 49 (96.1 %)
Gemcitabine-carboplatin 44 (86.3 %)
Paclitaxel-carboplatin 2 (3.9 %)
Docetaxel-carboplatin 1 (2.0 %)
Gemcitabine-Paclitaxel 1 (2.0 %)
Other 1 (2.0 %)
Table 6 Reason(s) for choosing vinflunine for management of a
patient following progression/relapse to an initial platinum-based
chemotherapy
Reason(s) for choosing vinflunine for management of a patient after
progression/relapse to an initial platinum-based chemotherapy, n = 51
physicians (0 up to a maximum of 3 reasons could be given)
Phase III evidence 34 (66.7 %)
Safety profile 21 (41.2 %)
Survival benefit 15 (29.4 %)
Drug approval 13 (25.5 %)
Guidelines 12 (23.5 %)
Progression free survival 11 (21.6 %)
Convenience of administration 9 (17.6 %)
Good prior experience 6 (11.8 %)
Best efficacy expectations 5 (9.8 %)
Symptoms control 4 (7.8 %)
Quality of life 3 (5.9 %)
Simple scheme 3 (5.9 %)
Handable schedule 2 (3.9 %)
Disease stabilization rate 1 (2.0 %)
Patient/family request/other reason -
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PS ≥ 2 or with comorbidities. In addition, there is no
strong phase III scientific evidence supporting the few
combination therapy options that are used in practice
while there are no recommendations based on recently
established prognostic factors. As a consequence, prac-
tices vary.
Three out of the four chosen countries for this study
(France, Italy and Spain) are among the 5 major coun-
tries for incidence and mortality from bladder cancer in
the European Union, the others being Germany and the
United Kingdom [3]. In order to have centers represen-
tative of actual care of advanced UC, the number of cen-
ters contacted per country was proportional to the
published country bladder cancer-related mortality.
The proportion of recruited patients closely mirrored
the incidence and mortality of bladder cancer in the four
participating countries [3] with slight variations: Aus-
trian patients number was above expectations and
French patients were less represented.
Possible selection biases have been limited through the
inclusion of all consecutive patients in each center, over
a maximum time corresponding to the study duration.
However it is possible that patients in very poor health
conditions, not able to attend an oncologic/urologic
visit, were not included in the study.
This study provides important insights on the type of
UC patients who receive platinum treatments in Europe.
A majority of patients (63 %) received a first platinum-
based chemotherapy regimen as palliative treatment in
the advanced or metastatic stage.
At the time of first systemic chemotherapy decision,
65 % of the patients were theoretically fit to receive cis-
platin but only 56 % of them received a cisplatin-based
therapy. The contra-indications to cisplatin treatment
are well-known but their respective frequencies in this
population of patients have never been reported. In this
survey, it was observed that 70 % of cisplatin-unfit pa-
tients had a single adverse condition for cisplatin use, ei-
ther renal impairment (58 %) or a PS ≥ 2 (12 %), while
hearing impairment was considered as single or com-
bined reason in only 5 %.
The observed response rate in the survey (45 %) mirrors
the expected response rates of 46 % with the MVAC regi-
men and 49 % with the gemcitabine-cisplatin regimen [16]
but is quite important considering the rate of patients
who did not receive a cisplatin-based regimen (43 %).
In the picture taken at registration, 80 % of patients
receive a second anticancer systemic treatment. The
post-platinum therapy was most often a single agent
after chemotherapy administered in the advanced/meta-
static setting, and preferably a cytotoxic combination
after a neoadjuvant or adjuvant chemotherapy regimen.
PS and prior response to chemotherapy were the main
parameters that influenced treatment decisions (both
>50 %) after a platinum-based therapy. The other pub-
lished second-line prognosis factors (hemoglobinemia,
liver metastasis) [13] were considered as impacting the
treatment choice in less than 7 % of cases. When consid-
ering the univariate and multivariate analyses testing the
association between patient characteristics and the deci-
sion of subsequent single agent or polychemotherapy
regimen, the strongest association was found with re-
sults achieved with the first treatment (objective re-
sponse and time to progression). Age (< or ≥ 75) did not
impact on the choice of treating patients with single-
agent or combination. Surprisingly, PS did not appear as
an influencing factor; this may be due to the limited
number of patients with PS ≥ 2 and/or to the fact that
most patients treated by combination therapy or by vin-
flunine are PS 0 or 1.
The most frequent chemotherapy regimen after plat-
inum was single agent vinflunine (42 % of all second anti-
cancer systemic treatments). Taxanes (mainly paclitaxel)
are still used as single agent but represent only 13 % of
post-platinum chemotherapy treatments.
As of today, and outside of clinical trials, single agent
therapy remains a standard in second-line treatment; ac-
tually chemotherapy doublets did not demonstrate ex-
tended survival rates even though they had shown
higher response rates in phase II studies [17]. Regimens
varied widely in cases where a combination therapy was
administered in post-platinum setting, carboplatin being
used quite often.
The real-life conditions of this study show that the
health status and prognosis of patients seen in routine
practice, are not worse than those of patients participat-
ing to the pivotal phase III vinflunine trial [18], in which
PS 2 patients were excluded. Patients with PS 0-1- ≥ 2
were 36 %-47 %-17 % here vs 28 %-72 %-0 % in the
phase III trial. Renal impairment (as defined by a cre-
atinine clearance < 60 mL/min) was 44 % vs 47 %. The
population in this survey showed relatively low visceral
metastases involvement, with only 13 % patients present-
ing hepatic metastases (vs 29 % in the pivotal phase III).
Another adverse prognosis factor, hemoglobinemia <
10 g/dL was reported in only 16 % of patients in this
study as compared to 86 % in the phase III trial.
After platinum-based chemotherapy failure, vinflunine
is the only chemotherapeutic agent approved in Europe.
The approval was based on a randomized phase III trial
investigating vinflunine plus best supportive care (BSC)
versus BSC alone [18]. The results showed clinical bene-
fit with a favorable safety profile and a survival benefit in
favor of vinflunine, which was statistically significant in
the eligible patient population, with a 22 % reduction of
the risk of death being achieved [19].
Recently, different prospective or retrospective studies of
vinflunine have been published, on the basis of German,
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Spanish, Greek and British series of patients receiving a
second-line treatment or more [20–23]. In these studies
patients with PS 2 represented 8–23 % and liver metastasis
was reported in 17–29 % of patients. Interesting response
rates were obtained, comprised between 13 and 29 % and
overall survival was between 7.7 and 11.9 months.
Second-line response rates obtained with taxanes, ifos-
famide, topotecan, pemetrexed and different tyrosine
kinase inhibitors have ranged between 0 and 28 % in
small phase II trials [24].
Gemcitabine displayed also interesting response rates
in second-line treatment, but most patients already re-
ceive this drug in first-line [25]. Paclitaxel/gemcitabine
studies have shown increased response rates, but no ran-
domized phase III trial with an adequate comparator
arm has been conducted to assess the true value and OS
benefit of this second-line combination [5, 26].
Checkpoint inhibitors, e.g. targeting the PD-1/PD-L1
axis, hold promising potential with good tolerability in
advanced UC [27]. Atezolizumab was recently ap-
proved in the United States by the Food and Drug Ad-
ministration [28] on the basis of a large phase II study
involving 310 patients with UC progressing following
platinum treatment [29]. This approval was granted in
a country where there was no approved drug in the
second-line setting. In Europe, no checkpoint inhibi-
tors have been approved yet for the treatment of UC.
Combining chemotherapies with immunotherapies may
provide valuable options with improved response rates
and tolerable toxicity.
Conclusion
This study conducted in four European countries reflects
daily practice in the treatment of patients with urothelial
carcinoma eligible for a first platinum-based chemother-
apy either in adjuvant/neoadjuvant or in advanced/
metastatic setting. It fills a knowledge gap on the charac-
teristics of UC patients treated with platinum agents and
on the reasons and modalities of further treatments. Cis-
platin was used in 56 % of patients. Cisplatin-ineligibility
appeared mainly due to renal dysfunction (68 %) and
PS ≥ 2 (21 %).
A second chemotherapy regimen was administered in
80 % of patients. Most often this was a single agent fol-
lowing an initial systemic chemotherapy administered in
the first-line advanced setting (70 % of patients); after a
neoadjuvant or adjuvant chemotherapy, the preference
was for a cytotoxic combination (60 % of patients). PS
and prior response to chemotherapy were the main pa-
rameters that influenced disease management. The most
frequent second systemic anticancer therapy was single
agent vinflunine (42 % of all subsequent systemic therap-
ies), the main reasons evoked by physicians being sur-
vival benefit, safety and phase III evidence.
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